Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.

Si-Cong MaXue BaiXue-Jun GuoLi LiuLu-Shan XiaoYan LinJia-Le TanXiao-Ting CaiYu-Xiang WenHu MaQ John FuMeng-Xin LengYan-Pei ZhangLi-Li LongZe-Qin GuoDe-Hua WuJian-Guo ZhouZhong-Yi Dong

Published in: BMC medicine (2022)

Organ-specific metastatic landscape served as a potential predictor of immunotherapy, and METscore might enable noninvasive forecast of PD-(L)1 blockade efficacy using baseline radiologic assessments in advanced NSCLC.

Keyphrases

advanced non small cell lung cancer
small cell lung cancer
clinical trial
epidermal growth factor receptor
squamous cell carcinoma
single cell
healthcare
primary care
tyrosine kinase
phase ii